Literature DB >> 17412386

Rift Valley fever virus lacking NSm proteins retains high virulence in vivo and may provide a model of human delayed onset neurologic disease.

Brian H Bird1, César G Albariño, Stuart T Nichol.   

Abstract

Rift Valley fever virus is a significant human and veterinary pathogen responsible for explosive outbreaks throughout Africa and the Arabian Peninsula. Severe acute disease in humans includes rapid onset hepatic disease and hemorrhagic fever or delayed onset encephalitis. A highly efficient reverse genetics system was developed which allowed generation of recombinant RVF viruses to assess the role of NSm protein in virulence in a rat model in which wild-type RVF virus strain ZH501 (wt-ZH501) results in 100% lethal hepatic disease 2-3 days post infection. While extensive genomic analysis indicates conservation of the NSm coding capability of diverse RVF viruses, and viruses deficient in NSs proteins are completely attenuated in vivo, comparison of wt-ZH501, a reverse genetics generated wt-ZH501 virus (R-ZH501), and R-ZH501 virus lacking the NSm proteins (R-DeltaNSm-ZH501) demonstrated that the NSm proteins were nonessential for in vivo virulence and lethality. Surprisingly, while 44% of R-DeltaNSm-ZH501 infected animals quickly developed lethal hepatic disease similar to wt- and R-ZH501, 17% developed delayed onset neurologic disease (lethargy, head tremors, and ataxia) at 13 days post infection. Such infections may provide the basis for study of both RVF acute hepatic disease and delayed onset encephalitic disease in humans.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17412386     DOI: 10.1016/j.virol.2007.01.046

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  66 in total

1.  Creation of a nonspreading Rift Valley fever virus.

Authors:  Jeroen Kortekaas; Nadia Oreshkova; Viviana Cobos-Jiménez; Rianka P M Vloet; Christiaan A Potgieter; Rob J M Moormann
Journal:  J Virol       Date:  2011-09-28       Impact factor: 5.103

2.  A shared transcription termination signal on negative and ambisense RNA genome segments of Rift Valley fever, sandfly fever Sicilian, and Toscana viruses.

Authors:  César G Albariño; Brian H Bird; Stuart T Nichol
Journal:  J Virol       Date:  2007-02-28       Impact factor: 5.103

Review 3.  Recent advances in the development of antiviral therapeutics for Rift Valley fever virus infection.

Authors:  Colm Atkins; Alexander N Freiberg
Journal:  Future Virol       Date:  2017-10-23       Impact factor: 1.831

4.  Interplay between the Virus and Host in Rift Valley Fever Pathogenesis.

Authors:  Kaori Terasaki; Shinji Makino
Journal:  J Innate Immun       Date:  2015-02-27       Impact factor: 7.349

5.  Rift Valley fever virus clearance and protection from neurologic disease are dependent on CD4+ T cell and virus-specific antibody responses.

Authors:  Kimberly A Dodd; Anita K McElroy; Megan E B Jones; Stuart T Nichol; Christina F Spiropoulou
Journal:  J Virol       Date:  2013-03-27       Impact factor: 5.103

Review 6.  Rift valley fever vaccines.

Authors:  Tetsuro Ikegami; Shinji Makino
Journal:  Vaccine       Date:  2009-11-05       Impact factor: 3.641

7.  NSs protein of rift valley fever virus induces the specific degradation of the double-stranded RNA-dependent protein kinase.

Authors:  Matthias Habjan; Andreas Pichlmair; Richard M Elliott; Anna K Overby; Timo Glatter; Matthias Gstaiger; Giulio Superti-Furga; Hermann Unger; Friedemann Weber
Journal:  J Virol       Date:  2009-02-11       Impact factor: 5.103

8.  Molecular biology of rift valley Fever virus.

Authors:  Michele Bouloy; Friedemann Weber
Journal:  Open Virol J       Date:  2010-04-22

9.  Rift Valley fever virus NSs protein promotes post-transcriptional downregulation of protein kinase PKR and inhibits eIF2alpha phosphorylation.

Authors:  Tetsuro Ikegami; Krishna Narayanan; Sungyong Won; Wataru Kamitani; C J Peters; Shinji Makino
Journal:  PLoS Pathog       Date:  2009-02-06       Impact factor: 6.823

10.  A replication-incompetent Rift Valley fever vaccine: chimeric virus-like particles protect mice and rats against lethal challenge.

Authors:  Robert B Mandell; Ramesh Koukuntla; Laura J K Mogler; Andrea K Carzoli; Alexander N Freiberg; Michael R Holbrook; Brian K Martin; William R Staplin; Nicholas N Vahanian; Charles J Link; Ramon Flick
Journal:  Virology       Date:  2009-11-24       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.